Delving into the Latest Updates on Human cord derived MSC cells (Hamilton Biotech) with Synapse

Overview

Basic Info

Drug Type

Mesenchymal stem cell therapy

Synonyms

UC-MSCs(Hamilton Biotech)

Target-

Action-

Mechanism-

Therapeutic Areas

Immune System DiseasesSkin and Musculoskeletal DiseasesEndocrinology and Metabolic Disease+ [1]

Active Indication

Osteoarthritis, KneeDiabetic NephropathiesPrimary Ovarian Insufficiency

Inactive Indication-

Originator Organization

Wuhan Hamilton Biotechnology Co., Ltd.

Active Organization

Wuhan Hamilton Biotechnology Co., Ltd.

Inactive Organization-

License Organization-

Drug Highest PhasePhase 2

First Approval Date-

Regulation-

Login to view timeline

（1）评价人脐带间充质干细胞注射液治疗膝关节骨性关节炎的有效性；（2）评价人脐带间充质干细胞注射液治疗膝关节骨性关节炎的安全性，为后续确证性临床试验推荐合适的细胞治疗剂量；（3）评价人脐带间充质干细胞注射液治疗膝关节骨性关节炎的免疫原性。

[Translation]

(1) Evaluate the effectiveness of human umbilical cord mesenchymal stem cell injection in the treatment of knee osteoarthritis; (2) Evaluate the safety of human umbilical cord mesenchymal stem cell injection in the treatment of knee osteoarthritis, and recommend appropriate cell therapy doses for subsequent confirmatory clinical trials; (3) Evaluate the immunogenicity of human umbilical cord mesenchymal stem cell injection in the treatment of knee osteoarthritis.

Start Date25 Jul 2025

Sponsor / Collaborator

Guangzhou Hamilton Biotechnology Co., Ltd.

[+1]

CTR20240763

/ Active, not recruitingPhase 1

人脐带间充质干细胞注射液治疗膝关节骨性关节炎的单中心、开放、剂量递增 I 期临床试验

[Translation] A single-center, open-label, dose-escalation phase I clinical trial of human umbilical cord mesenchymal stem cell injection in the treatment of knee osteoarthritis

主要目的：评价人脐带间充质干细胞注射液治疗膝关节骨性关节炎的安全性和耐受性，为 II 期临床试验推荐合适的细胞治疗剂量（RP2D）。次要目的：评价人脐带间充质干细胞注射液治疗膝关节骨性关节炎的初步有效性。评价人脐带间充质干细胞注射液治疗膝关节骨性关节炎的免疫原性。

[Translation]

Primary objective: To evaluate the safety and tolerability of human umbilical cord mesenchymal stem cell injection in the treatment of knee osteoarthritis, and to recommend an appropriate cell therapy dose (RP2D) for Phase II clinical trials. Secondary objective: To evaluate the preliminary efficacy of human umbilical cord mesenchymal stem cell injection in the treatment of knee osteoarthritis. To evaluate the immunogenicity of human umbilical cord mesenchymal stem cell injection in the treatment of knee osteoarthritis.

Start Date03 Jun 2024

Sponsor / Collaborator

Guangzhou Hamilton Biotechnology Co., Ltd.

[+1]

CTR20254262

/ Not yet recruitingPhase 1

人脐带间充质干细胞注射液治疗糖尿病肾病的单中心、开放、剂量递增I期临床试验

[Translation] A single-center, open-label, dose-escalation phase I clinical trial of human umbilical cord mesenchymal stem cell injection for the treatment of diabetic nephropathy.

主要目的：（1）评价人脐带间充质干细胞注射液治疗糖尿病肾病的安全性和耐受性，为II期临床试验推荐合适的细胞治疗剂量（RP2D）。次要目的：（1）评价人脐带间充质干细胞注射液治疗糖尿病肾病的初步有效性；（2）评价人脐带间充质干细胞注射液治疗糖尿病肾病的免疫原性。

[Translation]

Primary Objectives: (1) To evaluate the safety and tolerability of human umbilical cord mesenchymal stem cell injection for the treatment of diabetic nephropathy, and to recommend an appropriate cell therapy dose (RP2D) for a phase II clinical trial. Secondary Objectives: (1) To evaluate the preliminary efficacy of human umbilical cord mesenchymal stem cell injection for the treatment of diabetic nephropathy; (2) To evaluate the immunogenicity of human umbilical cord mesenchymal stem cell injection for the treatment of diabetic nephropathy.

Start Date-

Sponsor / Collaborator

Wuhan Hamilton Biotechnology Co., Ltd.

100 Clinical Results associated with Human cord derived MSC cells (Hamilton Biotech)

Login to view more data

100 Translational Medicine associated with Human cord derived MSC cells (Hamilton Biotech)

Login to view more data

100 Patents (Medical) associated with Human cord derived MSC cells (Hamilton Biotech)

Login to view more data

100 Deals associated with Human cord derived MSC cells (Hamilton Biotech)

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Osteoarthritis, Knee	Phase 2	China	Wuhan Hamilton Biotechnology Co., Ltd.	25 Jul 2025
Diabetic Nephropathies	Phase 1	China	Wuhan Hamilton Biotechnology Co., Ltd.	30 Oct 2025
Primary Ovarian Insufficiency	Phase 1	China	Wuhan Hamilton Biotechnology Co., Ltd.	24 Oct 2025